CIK 0000874015 · Large accelerated filer
IONIS PHARMACEUTICALS INC
Sign in to watch- Ticker
- IONS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 330336973
- Phone
- 7609319200
- Business address
- 2855 GAZELLE COURT, CARLSBAD, CA, 92010
- Former names
- ISIS PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $148,200
- in 1 filing
- Open-market sales, last 90 days
- $61,389
- in 2 filings
Net +$86,811. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-07 | Devers Shannon L. EVP, Chief Human Resources Ofc | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −3,460 | 7,879 | ||
| 2026-01-07 | Devers Shannon L. EVP, Chief Human Resources Ofc | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −3,829 | 9,254 | ||
| 2026-01-07 | Devers Shannon L. EVP, Chief Human Resources Ofc | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −9,264 | 9,262 | ||
| 2026-01-07 | Devers Shannon L. EVP, Chief Human Resources Ofc | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −25,545 | 2,971 | ||
| 2026-01-02 | Kordasiewicz Holly B. EVP, Chief Development Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +7,500 | 16,600 | ||
| 2026-01-02 | Jenne Kyle EVP, Chf GL Pdt Str Ofcr | Grant or award · Non-Qualified Stock Option (right to buy) | +19,350 | 19,350 | ||
| 2026-01-02 | Swayze Eric EVP Research | Option exercise 10b5-1 | +5,125 | $60.89 | $312K | 35,578 |
| 2026-01-02 | Swayze Eric EVP Research | Sale 10b5-1 | −5,125 | $78.57 | $403K | 30,453 |
| 2026-01-02 | Swayze Eric EVP Research | Option exercise 10b5-1 | +18,338 | $60.89 | $1.1M | 48,791 |
| 2026-01-02 | Swayze Eric EVP Research | Sale 10b5-1 | −18,338 | $79.27 | $1.5M | 30,453 |
| 2026-01-02 | Swayze Eric EVP Research | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −5,125 | 22,403 | ||
| 2026-01-02 | Swayze Eric EVP Research | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −18,338 | 4,065 | ||
| 2026-01-02 | Swayze Eric EVP Research | Grant or award · Non-Qualified Stock Option (right to buy) 10b5-1 | +19,350 | 19,350 | ||
| 2026-01-02 | Swayze Eric EVP Research | Grant or award · Non-Qualified Stock Option (right to buy) 10b5-1 | +150 | 150 | ||
| 2026-01-02 | Schneider Eugene EVP, Chf Clinical Develop Ofcr | Grant or award · Non-Qualified Stock Option (right to buy) | +19,350 | 19,350 | ||
| 2026-01-02 | O'NEIL PATRICK R. EVP CLO & General Counsel | Grant or award · Non-Qualified Stock Option (right to buy) | +19,350 | 19,350 | ||
| 2026-01-02 | Monia Brett P Chief Executive Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +85,410 | 85,410 | ||
| 2026-01-02 | Kordasiewicz Holly B. EVP, Chief Development Officer | Grant or award · Non-Qualified Stock Option (right to buy) | +9,100 | 9,100 | ||
| 2026-01-02 | HOUGEN ELIZABETH L EVP, Finance & CFO | Grant or award · Non-Qualified Stock Option (right to buy) | +25,770 | 25,770 | ||
| 2026-01-02 | Devers Shannon L. EVP, Chief Human Resources Ofc | Grant or award · Non-Qualified Stock Option (right to buy) | +19,350 | 19,350 |
Page 17 of 18 · 360 trades